Bleeding Disorders
From the Journals
Study finds lower quality of life for patients with hemophilia A
Patients with hemophilia A reported lower health-related quality of life even though they were receiving standard treatment.
From the Journals
New recommendations on immune tolerance induction in hemophilia A
A nine-member expert panel recommended the concurrent use of factor VIII replacement therapy and emicizumab to inhibit bleeding with lower-dose...
From the Journals
Study identifies GI bleed risk factors in von Willebrand disease
The most significant cause of GI bleeding in patients with von Willebrand disease was angiodysplasia.
Conference Coverage
LentiGlobin reduces transfusion dependence in young thalassemia patients
NEW ORLEANS – Children and young adults with non-beta0/beta0 thalassemia achieved transfusion independence in two trials.
Conference Coverage
TTP death linked to elevated troponin and neurological signs
GLASGOW – The registry-based study showed that more than 70% of patients who presented with thrombotic thrombocytopenic purpura had neurological...
From the Journals
Extended half-life clotting factors cut infusions, hike prices
The use of extended half-life clotting factors was able to significantly reduce the number of infusions but the cost went up significantly.
From the Journals
HAVEN 4: Monthly emicizumab shows value
Emicizumab was effective as a monthly treatment for patients with hemophilia A, both with and without inhibitors, according to an ongoing phase 3...
From the Journals
New consensus recommendations on vaccination in hemophilia
Vaccination in patients with hemophilia should be provided on the same institutional schedule but planning should take into account disease-...
From the Journals
Study explores intracranial hemorrhage management in type 2 VWD
The case report on spontaneous intracranial hemorrhage in a patient with type 2B von Willibrand disease illustrates the lack of standard...
From the Journals
Genetic analysis detects novel gene mutations in hemophilia A
Researchers identified two novel mutations that resulted in a severe phenotype of hemophilia A.
From the Journals
Platelet-rich plasma shows promise in hemophilic arthropathy of the knee
A single injection of platelet-rich plasma performed better on measures of function and pain than did weekly injections of hyaluronic acid.